FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 445 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... January 18, 2022 Nivolumab Injections Could Make Treatment Easier for More People with Cancer March 13, 2024 Bjorn Saven: “By supporting early career researchers to do their jobs... November 19, 2021 癌症可以在家族成员中被遗传吗？ October 13, 2020 Load more HOT NEWS Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does... Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab...
